Project Grant R01HL178097
Award Date 9/23/25
Completion Date 8/31/27
Dollars Obligated $1.5M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $722,667 project grant to the University of Texas Health Science Center at Houston (UTHealth) to conduct research on ribosome dysfunction in lung fibrosis associated with systemic sclerosis (SSc). The 5-year project, spanning from September 1, 2025 to May 31, 2030, aims to investigate the mechanisms by which enhanced ribosome biogenesis leads to an altered...
- This federal Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) provides $693,558 to the University of California, Los Angeles (UCLA) to validate the use of specific circulating biomarkers as functional response indicators for patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The research aims to identify reliable early-stage biomarkers that can signal therapeutic efficacy,...
- This $761,615 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of biological sex in the heterogeneity of Acute Respiratory Distress Syndrome (ARDS). The research team at Massachusetts General Hospital aims to determine how increased alveolar epithelial expression of Secretory Leukocyte Protease Inhibitor (SLPI) in females may increase epithelial glycocalyx resilience, leading to a...
- This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $168,048 to Yale University to conduct research on investigating platelet immune mechanisms in sickle cell disease. The primary goals are to 1) characterize heterogeneous platelet subpopulations and their contribution to vaso-occlusive disease in sickle cell patients, and 2) investigate specific immunothrombotic pathways and mechanisms of platelet activation...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $958,850 to Yale University to conduct research aimed at interrupting pro-inflammatory pulmonary-vascular cell interactions in order to reduce pulmonary capillary leak in critically ill children with bronchiolitis. The overarching goal is to understand the regulation of interleukin-1 (IL-1) signaling in bronchiolitis, establish disease severity markers, and...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of heterochromatin dynamics in the plasticity of vascular smooth muscle cells (SMCs). The $756,224 grant, awarded to Yale University on August 15, 2025, will fund investigations into how epigenetic regulation of heterochromatin, particularly through the histone methyltransferase SUV39H1, influences SMC phenotypic transitions. The...
- This Project Grant award of $147,400.00, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the mechanisms by which antigen non-related CD4+ T cells contribute to the pathogenesis of skin fibrosis in systemic sclerosis (scleroderma) and sclerodermoid graft-versus-host disease. The project, conducted by Yale University, will use mouse models to...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...